Duravyu at two dose levels met its primary endpoint in the treatment of diabetic macular edema in a phase 2 clinical trial, according to a press release from EyePoint Pharmaceuticals.
“Duravyu (EYP-1901) features vorolanib, which blocks the activity of all isoforms of VEGF by blocking all VEGF receptors,” Jay S. Duker, MD, president and CEO of EyePoint, told Healio. “Due to the unique design, the drug release is constant for at least 6 months. This should enable the majority of DME patients to enjoy stable vision with fewer visits and (Read more...)